Ameriprise
BBIO icon

Ameriprise’s BridgeBio Pharma BBIO Stock Holding History

Ameriprise’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.7M Buy
1,248,521
+406,985
+48% +$29.5M 0.02% 584
2025
Q4 		$64.4M Buy
841,536
+40,855
+5% +$2.68M 0.01% 751
2025
Q3 		$41.6M Buy
800,681
+13,637
+2% +$665K 0.01% 997
2025
Q2 		$34M Sell
787,044
-254,891
-24% -$9.27M 0.01% 1063
2025
Q1 		$36M Buy
1,041,935
+608,856
+141% +$20.5M 0.01% 998
2024
Q4 		$11.9M Sell
433,079
-17,302
-4% -$447K ﹤0.01% 1669
2024
Q3 		$11.5M Buy
450,381
+415,606
+1,195% +$10.9M ﹤0.01% 1673
2024
Q2 		$881K Buy
34,775
+45
+0.1% +$1.23K ﹤0.01% 3200
2024
Q1 		$1.07M Sell
34,730
-80
-0.2% -$2.72K ﹤0.01% 3133
2023
Q4 		$1.41M Buy
34,810
+300
+0.9% +$9.01K ﹤0.01% 3048
2023
Q3 		$910K Sell
34,510
-1,645
-5% -$46.7K ﹤0.01% 3184
2023
Q2 		$622K Sell
36,155
-1,465
-4% -$22K ﹤0.01% 3358
2023
Q1 		$624K Sell
37,620
-23,097
-38% -$269K ﹤0.01% 3340
2022
Q4 		$463K Sell
60,717
-530
-0.9% -$5.07K ﹤0.01% 3436
2022
Q3 		$609K Buy
61,247
+42,052
+219% +$437K ﹤0.01% 3313
2022
Q2 		$174K Buy
+19,195
New +$161K ﹤0.01% 3706
2022
Q1 		– Sell
-40,372
Closed -$674K – 3939
2021
Q4 		$674K Sell
40,372
-1,440
-3% -$60.9K ﹤0.01% 3419
2021
Q3 		$1.96M Buy
41,812
+3,293
+9% +$177K ﹤0.01% 2881
2021
Q2 		$2.35M Buy
38,519
+3,308
+9% +$189K ﹤0.01% 2858
2021
Q1 		$2.17M Sell
35,211
-7,391
-17% -$484K ﹤0.01% 2826
2020
Q4 		$3.03M Sell
42,602
-1,637
-4% -$79K ﹤0.01% 2582
2020
Q3 		$1.66M Sell
44,239
-2,563
-5% -$80.6K ﹤0.01% 2763
2020
Q2 		$1.53M Sell
46,802
-11,690
-20% -$356K ﹤0.01% 2733
2020
Q1 		$1.7M Buy
58,492
+29,519
+102% +$915K ﹤0.01% 2564
2019
Q4 		$1.02M Buy
28,973
+1,429
+5% +$39.6K ﹤0.01% 3045
2019
Q3 		$591K Buy
27,544
+2,429
+10% +$67.2K ﹤0.01% 3244
2019
Q2 		$677K Buy
+25,115
New +$685K ﹤0.01% 3219

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's BBIO Position: Q1 2026 in Review

Ameriprise increased its BridgeBio Pharma (BBIO) stake by 48% in Q1 2026, buying an estimated $29.5M and bringing the position to 1,248,521 shares worth $92.7M. The position accounts for 0.02% of the portfolio, ranked #584.

Ameriprise first reported a position in BBIO in Q2 2019 and has held it in 27 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Ameriprise held 1,248,521 shares of BridgeBio Pharma worth $92.7M as of Q1 2026.
  • Ameriprise bought 406,985 BridgeBio Pharma shares in Q1 2026, an estimated $29.5M.
  • BridgeBio Pharma made up 0.02% of Ameriprise's portfolio in Q1 2026, its #584 holding.
  • Ameriprise first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 27 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.